The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Eteplirsen in the treatment of Duchenne muscular dystrophy
Open accessAbstract
Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500–5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers. In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacological, efficacy, safety, and tolerability data from preclinical and clinical trials. Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified. Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed. Keywords: Duchenne muscular dystrophy, eteplirsen, Exondys 51, exon-skipping therapy, phosphorodiamidate morpholino oligomers
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693 · cited 1×
“Duchenne muscular dystrophy (DMD): introduction and management issues in treatment DMD is a fatal X-linked recessive neuromuscular disorder characterized by progressive muscle weakening and wasting.(1) It affects around one in 3,500–5,000 males born worldwide.”
BackgroundKoenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988) · Cell · doi:10.1016/0092-8674(88)90383-2 · Cited by 1,538
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin
Ervasti, J., & Campbell, K. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.4.809 · Cited by 1,388
Membrane organization of the dystrophin-glycoprotein complex
Ervasti, J. M., & Campbell, K. P. (1991) · Cell · doi:10.1016/0092-8674(91)90035-w · Cited by 1,329
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Cited by
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
miRNA: A Promising Therapeutic Target in Cancer
Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L., & Naidu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911502 · Cited by 357
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects
Rogalska, M. E., Vivori, C., & Valcárcel, J. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00556-8 · Cited by 265
RNA therapy: rich history, various applications and unlimited future prospects
Kim, Y.-K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00757-5 · Cited by 264
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
Development of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251
Shimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010001 · Cited by 82
Self-citationSmart Nanocarriers for the Delivery of Nucleic Acid‐Based Therapeutics: A Comprehensive Review
Ramasamy, T., Munusamy, S., Ruttala, H. B., & Kim, J. O. (2021) · Biotechnology Journal · doi:10.1002/biot.201900408 · Cited by 76
RNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights
Ersöz, E., & Demir‐Dora, D. (2024) · Drug Development Research · doi:10.1002/ddr.22187 · Cited by 34
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Lim, K. R., Maruyama, R., & Yokota, T.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume11
- Pages
- 533-545
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2593956993
- Cited by
- 495
- References
- 53
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.